ConTiPi Medical

Company Overview

Snapshot

Founded in January 2014 by Elan Ziv, ConTiPi Medical operates with 1-10 employees. The company has secured funding across two rounds from five investors, including Capital Point. In June 2023, ConTiPi Medical raised structured capital to support the market launch of its ProVate device.

Business overview

ConTiPi Medical specializes in developing noninvasive and disposable vaginal devices for women experiencing pelvic floor disorders, such as stress urinary incontinence and pelvic organ prolapse. Its core products include the ProVate device for pelvic organ prolapse, which has received FDA 510(k) clearance and CE Mark, and a device for stress urinary incontinence previously sold to Kimberly Clark Worldwide Inc. The company operates within the Health Tech & Life Sciences sector, specifically targeting Medical Devices and Medical Treatment & Therapeutics, serving both healthcare providers and women consumers.

Strategic signal

In June 2023, ConTiPi Medical secured structured capital from Capital IP Investment Partners and Ghost Tree Partners. This financial injection and strategic alliance are critical for the market launch and commercialization of its ProVate device, signaling a strong push towards broader market penetration and revenue generation in the women's health sector.

Company Intelligence Q&A

What was the most recent funding event for ConTiPi Medical?

In June 2023, ConTiPi Medical raised structured capital from Capital IP Investment Partners and Ghost Tree Partners. This funding is intended to support the market launch of its ProVate device.

What is the ProVate device and its regulatory status?

The ProVate device is a non-surgical, disposable ring pessary solution designed for pelvic organ prolapse. It has received 510(k) clearance from the FDA for marketing in the United States and a CE Mark for marketing in the EU.

What is ConTiPi Medical's partnership with Indegene?

In May 2023, Indegene expanded its partnership with ConTiPi Medical to commercialize the ProVate device. Indegene provides comprehensive services across the commercialization process, including pricing, market access, medical communications, and omnichannel marketing solutions.

When did ConTiPi Medical receive FDA approval for its pelvic organ prolapse treatment?

In July 2019, ConTiPi Medical received FDA approval for the marketing of its product designed to treat pelvic organ prolapse in women.

What was a significant early achievement for ConTiPi Medical regarding its stress urinary incontinence device?

ConTiPi Medical's first device, designed for the management of stress urinary incontinence in women, was sold to Kimberly Clark Worldwide Inc. and is now marketed in North America under the name Poise Impressa.